Tonix Pharmaceuticals, a clinical-stage biopharmaceutical company, is planning on developing TNX-102 SL (cyclobenzaprine HCl sublingual tablets) to treat long Covid or post-acute sequelae of Covid-19 (PASC1). Tonix is expected to meet with the US Food and Drug Administration in the third quarter of 2021 to agree on a potential Phase II pivotal study and the clinical development of TNX-102 SL for long Covid treatment. TNX-102 SL is currently being evaluated to improve sleep quality in a Phase III study of fibromyalgia, for which interim analysis results of the second potential pivotal study are expected in the third quarter of 2021. Top-line results are expected in the first quarter of 2022.
Biotech Vaxxinity, along with UBI-Asia, have announced a purchase order with the government of Paraguay for its Covid-19 vaccine, UB-612. The agreement is expected to materialise on the basis of Taiwanese Food and Drug Administration’s issuance of an emergency use authorisation for the jab. The order to deliver one million doses of UB-612 was signed on 16 June 2021. The vaccine is the first multitope protein/synthetic peptide vaccine to fight against the SARS-CoV-2 virus.
Global WholeHealth Partners, a biotechnology company offering diagnostic testing services, has acquired the rights to sell and distribute the Pfizer-BioNTech Covid-19 vaccine from Nunzia Pharmaceutical. The company will function as a broker for Nunzia and follow the same sales order processing as used by Nunzia. The news comes shortly after Global WholeHealth Partner’s purchase of the rights to distribute Johnson & Johnson’s Covid-19 vaccine.